$12.77
1.20% day before yesterday
Nasdaq, Dec 27, 10:09 pm CET
ISIN
US87164F1057
Symbol
SNDX
Sector
Industry

Syndax Pharmaceuticals Inc Stock price

$12.77
-3.74 22.65% 1M
-7.55 37.16% 6M
-8.84 40.91% YTD
-8.90 41.07% 1Y
-9.19 41.85% 3Y
+3.83 42.84% 5Y
+0.76 6.33% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.16 1.20%
ISIN
US87164F1057
Symbol
SNDX
Sector
Industry

Key metrics

Market capitalization $1.09b
Enterprise Value $701.26m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 43.83
P/S ratio (TTM) P/S ratio 68.13
P/B ratio (TTM) P/B ratio 2.98
Revenue (TTM) Revenue $16.00m
EBIT (operating result TTM) EBIT $-321.21m
Free Cash Flow (TTM) Free Cash Flow $-258.86m
Cash position $389.61m
EPS (TTM) EPS $-3.63
P/E forward negative
P/S forward 30.48
EV/Sales forward 19.61
Short interest 17.00%
Show more

Is Syndax Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Syndax Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Syndax Pharmaceuticals Inc forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a Syndax Pharmaceuticals Inc forecast:

Buy
93%
Hold
7%

Financial data from Syndax Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
16 16
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 106 106
96% 96%
662%
- Research and Development Expense 231 231
66% 66%
1,445%
-321 -321
66% 66%
-2,008%
- Depreciation and Amortization 0.01 0.01
97% 97%
0%
EBIT (Operating Income) EBIT -321 -321
66% 66%
-2,008%
Net Profit -297 -297
69% 69%
-1,857%

In millions USD.

Don't miss a Thing! We will send you all news about Syndax Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Syndax Pharmaceuticals Inc Stock News

Neutral
PRNewsWire
10 days ago
NEW YORK , Dec. 19, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX). If you are a shareholder of Syndax Pharmaceuticals, Inc. and are interested in obtaining additional information reg...
Neutral
PRNewsWire
20 days ago
– Subgroup analyses from Ph 2 protocol-defined R/R mNPM1 AML efficacy population (N=64) show responses across all major subgroups, including heavily pretreated patients – – 26% CR+CRh (20/77) and 48% ORR (37/77) in all enrolled patients who met the efficacy evaluable criteria in Ph 2 R/R mNPM1 AML cohort – – 100% ORR (37/37) and 95% CRc (35/37) in BEAT AML trial exploring revumenib in combinati...
Neutral
PRNewsWire
21 days ago
–        82% ORR (27 of 33 pts) and 48% CR/CRh (16 of 33 pts) in SAVE trial studying revumenib in combination with venetoclax and decitabine/cedazuridine in R/R AML – –        64% ORR (62 of 97 pts) and 23% CR/CRh (22 of 97 pts) with high rates of MRD negativity and ability to proceed to HSCT in expanded dataset of Ph 2 R/R KMT2Ar acute leukemia patients in AUGMENT-101 – –         Responses wer...
More Syndax Pharmaceuticals Inc News

Company Profile

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include candidate and entinostat. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.

Head office United States
CEO Michael Metzger
Employees 184
Founded 2005
Website www.syndax.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today